BioLab
고려대학교 약학대학 Drug Discovery Lab
장재봉 교수
연구실 소개
연구실 홈페이지The Jang lab develops first-in-class chemical probes and best-in-class drug candidates that are utilized to study cellular processes related to cancer and other diseases, and to control a specific target protein causing diseases such as various cancers, obesity and infectious diseases by combined tools of medicinal chemistry, computational approach, biochemistry, molecular and cellular biology. In particular, our lab is focusing on the development of novel kinase inhibitors based on new chemical scaffolds to target drug-resistant mutants of well-studied kinases, or orphan kinases. The development of a leading-edge platform of ‘proximity-based therapeutics’ which enables us to discover molecular glues and bifunctional molecules utilized in the targeted protein degradation approach is another main topic of our research. Additionally, we investigate novel synthetic methods that are capable of efficient synthesis of diverse chemical analogs, protein-drug conjugates, as well as complex natural products.
Prof. JAEBONG JANG (장재봉 교수)
Assistant Professor, College of Pharmacy Korea University
Professional Experience & Education
12/2019 - current : Assistant Professor College of Pharmacy Korea University Korea
09/2019 - 12/2019 : Adjunct Instructor College of Pharmacy Korea University Korea
07/2018 - 12/2019 : Research Fellow Institute for Basic Science Korea (Advisor. Prof. Sungwoo Hong)
12/2013 - 07/2018 : Research Fellow Dana-Farber Cancer Institute / Harvard Medical School USA (Advisor. Prof. Nathanael S. Gray)
09/2012 - 12/2013 : Senior Researcher Research Institute of Pharmaceutical Sciences
Seoul National University Korea
03/2006 - 08/2012 : Integrated M.S. and Ph.D. in Pharmacy College of Pharmacy Seoul National University (Advisor. Prof. Young-Ger Suh)
03/2002 - 02/2006 : B. S. in Pharmacy College of Pharmacy Seoul National University
연구분야
1. TARGETING KINASES
Since imatinib developed, a lot of kinase inhibitors have been developed especially in oncology field. And the tool-kits available for determination of potency or selectivity accelerate the development of new kinase inhibitors. Currently, our lab is working on developing new kinase inhibitors based on novel chemical scaffolds to target drug-resistant mutants of well-studied kinases or orphan kinases.
2. TARGETED PROTAIN DEGRADATION
Targeted Protein Degradation is on one of the most innovative approaches in drug discovery since its mechanism of action is totally different with traditional small molecule drugs. We are developing leading-edge platforms that are capable of discovering molecular glues or bifunctional molecules enabling targeted degradation of disease-relevant proteins of interest.
3. TOTAL SYNTHESIS OF NATURAL PRODUCT
The total synthesis of biologically active natural products is one of the dynamic area in the chemical synthesis. The development of novel synthetic route of a complex natural product provides an opportunity of finding novel synthetic methodology and obtaining a large scale of the natural product.
4. DEVELOPMENT OF NOVEL SYNTHETIC METHODOLOGY
Synthetic methodology refers to the methods used for the synthesis of chemical compounds. Although countless synthetic methods have been developed, this field is still one of the highly competitive and fast-growing areas in organic chemistry.
연구성과
최근 5년, 2019~현재
- 2022
Prospect of ULK1 modulators in targeting regulatory T cells. Y Park*, J Jang* Bioorg. Chem. (2022) accepted
Cell extraction method coupled with LC-QTOF MS/MS analysis for predicting neuroprotective compounds from Polygonum tinctorium. H Shin, J Jang, M K Lee, K Y Lee J Pharm Biomed Anal (2022) 220, 114988
Recent advances in the development of antidepressants targeting the purinergic P2X7 receptor. S Lee, H Ha, J Jang, Y Byun Curr Med Chem (2022) in press
Molecular basis for cooperative binding and synergy of ATP-site and allosteric EGFR inhibitors. T S Beyett, C To, D E Heppner, J K Rana, A M Schmoker, J Jang, D J H De Clercq, G Gomez, D A Scott, N S Gray, P A Janne, M J Eck Nat. Commun. (2022) 13, 2530
Quinazolinones as allosteric fourth-generation EGFR inhibitors for the treatment of NSCLC. T W Gero, D E Heppner, T S Beyett, C To, S C Azevedo, J Jang, T Bunnell, F Feru, Z Li, B H Shin, K M Soroko, P C Gokhale, N S Gray, P A Janne, M J Eck, D A Scott B Bioorg. Med. Chem. Lett. (2022) 68, 128718
Allosteric Inhibition of Drug Resistant Forms of EGFR L858R mutant NSCLC. C To†, T S Beyett†, J Jang†, W W Feng, M Bahcall, H M Haikala, B H Shin, D E Heppner, J K Rana, B A Leeper, K M Soroko, M J Poitras, P C Gokhale, Y Kobayashi, K Wahid, K J Kurppa, T W Gero, M D Cameron, A Ogino, M Mushajiang, C Xu, Y Zhang, D A Scott, M J Eck, N S Gray, P A Janne Nature Cancer (2022) 3, 402-417
A novel HER2-selective kinase inhibitor is effective in HER2 mutant and amplified non-small cell lung cancer. J Son, J Jang, T S Beyett, Y Eum, H M Haikala, A Verano, M Lin, J M Hatcher, N P Kwiatkowski, P O Eser, M J Poitras, S Wang, M Xu, P C Gokhale, M D Cameron, M J Eck, N S Gray, P A Janne Cancer Res. (2022) 82, 1633-1645
- 2021
Surveillance of avian influenza viruses from 2009 to 2013 in South Korea. J-H Nam, E Espano, E-J Song, S-M Shim, W Na, S-H Jeong, J Kim, J Jang, D Song, J-K Kim Sci. Rep. (2021) 11, 23991
Neural-Cadherin Influences the Homing of Terminally Differentiated Memory CD8 T Cells to the Lymph Nodes and Bone Marrow. K H Kim, A Choi, S H Kim, H Song, S Jin, K Kim, J Jang, H Choi, Y W Jung Mol. Cells (2021) 44, 795
A Review on Pharmacological Activities and Recent Synthetic Advances of γ-Butyrolactones. J Hur, J Jang*, J Sim*. Int. J. Mol. Sci. (2021) 22, 2769
Inhibitors of prostate-specific membrane antigen in the diagnosis and therapy of metastatic prostate cancer - a review of patent literature. H Ha, H Kwon, T Lim, J Jang, S-K Park, Y Byun. Expert Opin. Ther. Pat. (2021) 31, 2525-2547
Structure-Activity Relationship Studies of Dipeptide-Based Hepsin Inhibitors with Arg Bioisosteres. H Kwon, H Ja, J Jeon, J Jang, S-H Son, K Lee, S-K Park, Y Byun. Bioorg. Chem. (2021) 107, 104521
- 2020
Visible-Light-Induced Cysteine-Specific Bioconjugation: Biocompatible Thiol-Ene Click Chemistry. H Choi, M Kim, J Jang*, S. Hong*. Angewandte Chemie Int. Ed. (2020) 59, 22514-22522. *co-corresponding author
Mutant-Selective Allosteric EGFR Degraders are Effective Against a Broad Range of Drug-Resistant Mutations. J Jang†, C To† , D J H De Clercq, E Park, C M Ponthier, B H Shin, M Mushajiang, R P Nowak, E S Fischer, M J Eck, P A Janne*, N S Gray*. Angewandte Chemie Int. Ed. (2020) 59, 14481-4489. †equal contribution
- 2019
Discovery and Optimization of Dibenzodiazepinones as Allosteric Mutant-Selective EGFR Inhibitors. D J H De Clercq, D E Heppner, C To, J Jang, E Park, C-H Yun, M Mushajiang, B H Shin, T W Gero, D A Scott, P A Janne, M J Eck, N S Gray. ACS Med. Chem. Lett. (2019) 10, 1549-1553
Single and dual targeting of mutant EGFR with an allosteric inhibitor. C To†, J Jang†, T Chen, E Park, M Mushajiang, D J H De Clercq, M D Cameron, D E Heppner, A Yang, S E Dahlberg, K-K Wong, M J Eck, N S Gray, P A Janne. ‘ Cancer Discovery (2019) 9, 926-943. †equal contribution
Identification of small molecule inhibitors targeting the Zika virus envelope protein. J Pitts, C-Y Hsia, W Lian, J Wang, M-P Pfeil, N Kwiatkowski, Z Li, J Jang, N S Gray, P L Yang. Antiviral Res. (2019) 164, 147-153.
Small molecules targeting the flavivirus E protein with broad-spectrum activity and antiviral efficacy in Vivo. P-C Li†, J Jang†, C-Y Hsia, P Groomes, W Lian, M de Wispelaere, J D Pitts, J Wang, N Kwaitkowski, N S Gray, P L Yang. ACS Infectious Diseases (2019) 5, 460-472. †equal contribution
Discovery of fluorescent 3-heteroarylcoumarin derivatives as novel inhibitors of anaplastic lymphoma kinase. S Mah, J Jang, D Song, Y Shin, M Latif, Y Jung, S Hong. Org. Biomol. Chem. (2019) 17, 186-194.
연구실 구성원
하고싶은 이야기
본 정보는 해당 기관에서 제공한 자료를 바탕으로 구성된 내용으로, BRIC에서 자체 생산한 정보가 아님을 밝혀드립니다.
소개된 내용에서 중요하게 판단되는 부분은 해당 기관에 추가적으로 사실 확인 작업을 하시길 부탁드립니다.
내용의 업데이트 또는 변경을 원하시면 관리자(interview@ibric.org)에게 연락 바랍니다.